{"id":10006,"date":"2026-10-30T16:51:00","date_gmt":"2026-10-30T11:21:00","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/onesource-share-price-today-2026-10-30\/"},"modified":"2026-10-30T16:51:02","modified_gmt":"2026-10-30T11:21:02","slug":"onesource-share-price-today-2026-10-30","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/onesource-share-price-today-2026-10-30\/","title":{"rendered":"Onesource Specialty Pharma Share Price Today: Rises 18.79% in 5 Trading Sessions | 30 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ONESOURCE<\/strong> \u00b7 30 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,584.80<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+0.97%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,598.10 \/ \u20b91,541.20<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,569.60<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>9.52 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>30 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Onesource Specialty Pharma has risen 18.79% over 5 trading sessions; today&#x27;s move is +0.97%.<\/li>\n<li>The company reported its consolidated financial results for the quarter ended September 30, 2026, posting revenues of \u20b95,162 million, up 37% year-on-year, and EBITDA of \u20b91,633 million, up 53% year-on-year. Management highlighted that growth was driven by new drug-device combination (DDC) capacity, strong master service agreement execution, and 12 product launches across global markets.<\/li>\n<li>Trading volume was 1.21 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Onesource Specialty Pharma share price: 18.79% rise over 5 trading sessions<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Onesource Specialty Pharma Ltd. (ONESOURCE) moved higher during the trading session, gaining 0.97% to close at \u20b91,584.80 compared to its previous close of \u20b91,569.60. The stock opened at \u20b91,579.00 and moved within an intraday range of a low of \u20b91,541.20 and a high of \u20b91,598.10.<\/p>\n<p class=\"wt-copy\">The broader market and sector environment showed positive momentum, with the benchmark Nifty rising 0.51% and the Nifty Pharma sector gaining 1.55% during the session. Onesource&#x27;s upward movement of 0.97% is broadly consistent with the supportive sector backdrop, though the stock has experienced notable volatility across shorter timeframes, posting a 5-day return of 18.79% and a 20-day return of 4.15% after prior session pullbacks of -0.51% and -1.27% over the preceding two days.<\/p>\n<p class=\"wt-copy\">Company disclosures provide relevant operational context, including a recent regulatory update on October 30, 2026, where the company announced the receipt of the Establishment Inspection Report (EIR) with a &#x27;Voluntary Action Indicated&#x27; (VAI) classification from the USFDA for its Sterile Product Division (SPD) facility in Bengaluru. This follows strong Q2FY27 financial results reported on October 27, 2026, which featured a 37% year-on-year increase in revenue to \u20b95,162 million and a 53% year-on-year rise in EBITDA to \u20b91,633 million, driven by new drug-device combination (DDC) capacity and broader segment execution.<\/p>\n<p class=\"wt-copy\">9.52 lakh shares traded by 30 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 7.86 lakh shares (1.21 times). The five-day average daily volume was 25.57 lakh shares. Separately, the NSE report for 29 October 2026 showed 4.63 lakh shares delivered, representing 62.85% of that day\u2019s traded volume. The same report recorded 40,707 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Positive regulatory update and follow-through from strong Q2 earnings within a gaining pharma sector<\/strong><\/p>\n<p class=\"wt-copy\">The 0.97% gain aligns with broader Nifty Pharma sector strength (+1.55%) and follows recent substantive disclosures regarding a clean USFDA inspection outcome for the Bengaluru facility and robust Q2FY27 revenue and EBITDA growth.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Strong Q2FY27 Results with 37% Revenue Growth<\/div>\n<div class=\"wt-card-date\">27 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company reported its consolidated financial results for the quarter ended September 30, 2026, posting revenues of \u20b95,162 million, up 37% year-on-year, and EBITDA of \u20b91,633 million, up 53% year-on-year. Management highlighted that growth was driven by new drug-device combination (DDC) capacity, strong master service agreement execution, and 12 product launches across global markets.<\/p>\n<p class=\"wt-copy\">Demonstrates robust operating leverage and scaling commercial volumes across key specialty pharmaceutical business segments.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Board Approves Change in Designation for Dr. Claudio Albrecht<\/div>\n<div class=\"wt-card-date\">27 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The Board of Directors approved the change in designation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director, subject to shareholder approval, drawing on his extensive three-decade experience in the global generics and pharmaceutical industry.<\/p>\n<p class=\"wt-copy\">Realigns board composition and leverages advisory expertise in pharmaceutical acquisitions and strategic investments.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">27 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 27, 2026, titled &quot;OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ONESOURCECDMO_27102026104146_OS_PR_IR.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">30.47%<\/div>\n<div class=\"wt-note\">30.48% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">19.46%<\/div>\n<div class=\"wt-note\">19.19% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">43.67%<\/div>\n<div class=\"wt-note\">42.57% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742818_21102026031128_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>PRONOMZ VENTURES LLP<\/strong><span class=\"wt-note\">Promoter Group<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>33,906 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>30 January 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Tenshi Pharmaceuticals Private Limited<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>75,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>30 January 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>TENSHI PHARMACEUTICALS PRIVATE LIMITED<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>85,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>4 February 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>PRONOMZ VENTURES LLP<\/strong><span class=\"wt-note\">Promoter Group<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>45,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>2 February 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>TENSHI PHARMACEUTICALS PRIVATE LIMITED<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>2.05 lakh shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>2 February 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 13.76% on 30 September 2026. This compares with 12.98% on 30 June 2026, a change of +0.78 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 25 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">MOTILAL OSWAL MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">80.49 lakh shares \u00b7 7.02%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">AXIS MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">15.88 lakh shares \u00b7 1.38%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">360 ONE MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">14.25 lakh shares \u00b7 1.24%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742818_21102026031128_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Commercial ramp-up and execution of the second DDC cartridge line and upcoming line 3 operations<\/li>\n<li>Global product launches and regulatory approval progress in regulated markets like Brazil, Turkey, and Canada<\/li>\n<li>Sustained delivery and cash volume trends relative to the 20-day average volume benchmark<\/li>\n<li>Biologics customer onboarding progress following recent wins with US biotech partners<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/onesource-share-price-today-2026-10-29\/\">Onesource Specialty Pharma Share Price Today: Rises 12.36% in 3 Trading Sessions | 29 October 2026 \u2014 29 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/onesource-share-price-today-2026-10-28\/\">Onesource Specialty Pharma Share Price Today: Rises 12.90% in 2 Trading Sessions | 28 October 2026 \u2014 28 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/onesource-share-price-today-2026-10-27\/\">Onesource Specialty Pharma Share Price Today: Rises 19.41% in 2 Trading Sessions | 27 October 2026 \u2014 27 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/onesource\/\">More Onesource Specialty Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Onesource Specialty Pharma company news?<\/h3>\n<p class=\"wt-copy\">The company reported its consolidated financial results for the quarter ended September 30, 2026, posting revenues of \u20b95,162 million, up 37% year-on-year, and EBITDA of \u20b91,633 million, up 53% year-on-year. Management highlighted that growth was driven by new drug-device combination (DDC) capacity, strong master service agreement execution, and 12 product launches across global markets.<\/p>\n<h3>How strong was Onesource Specialty Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">9.52 lakh shares traded, 1.21 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/onesource-share-price-today-2026-10-30\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/onesource-share-price-today-2026-10-30\/\"}, \"headline\": \"Onesource Specialty Pharma Share Price Today: Rises 18.79% in 5 Trading Sessions | 30 October 2026\", \"description\": \"Onesource Specialty Pharma has risen 18.79% over 5 trading sessions. Today it is 0.97% higher at \u20b91,584.80. See price context, volume and key company.\", \"datePublished\": \"2026-10-30T16:50:49.574137+05:30\", \"dateModified\": \"2026-10-30T16:50:49.574137+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Onesource Specialty Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"ONESOURCE\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/onesource-company-news-2026-10-30.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 30, 2026, titled \\\"OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru\\\".\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 14:10:44\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ONESOURCECDMO_30102026141033_OS_PR_USFDA_Approval.pdf\"}],\"recent_news\":[{\"summary\":\"a press release dated October 27, 2026, titled \\\"OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY\\\".\",\"category\":\"Press Release\",\"date\":\"27-Oct-2026 10:42:31\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ONESOURCECDMO_27102026104146_OS_PR_IR.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Onesource Specialty Pharma Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"27-Oct-2026 10:07:54\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ONESOURCECDMO_27102026100700_OS_Intimation_Outcome_of_BM_27Oct2026_s.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Onesource Specialty Pharma Limited has submitted the Exchange a copy Srutinizers report and voting results for the 19th AGM held on September 23, 2026.\",\"category\":\"Shareholders meeting\",\"date\":\"25-Sep-2026 18:00:02\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ONESOURCECDMO_25092026175945_OS_AGM_Voting_Results.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"a press release dated October 30, 2026, titled \\\"OneSource Receives USFDA EIR with VAI Classification, Marking Completion of Inspection Process at its Sterile Product Division (SPD) Facility in Bengaluru\\\".\",\"category\":\"Press Release\",\"date\":\"30-Oct-2026 14:10:44\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ONESOURCECDMO_30102026141033_OS_PR_USFDA_Approval.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"insider_activity\":[{\"person\":\"PRONOMZ VENTURES LLP\",\"category\":\"Promoter Group\",\"type\":\"Buy\",\"quantity\":\"33906\",\"post_holding\":\"2716308\",\"date\":\"30-Jan-2026\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Tenshi Pharmaceuticals Private Limited\",\"category\":\"Promoters\",\"type\":\"Buy\",\"quantity\":\"75000\",\"post_holding\":\"20799714\",\"date\":\"30-Jan-2026\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"TENSHI PHARMACEUTICALS PRIVATE LIMITED\",\"category\":\"Promoters\",\"type\":\"Buy\",\"quantity\":\"85000\",\"post_holding\":\"21089714\",\"date\":\"04-Feb-2026\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"PRONOMZ VENTURES LLP\",\"category\":\"Promoter Group\",\"type\":\"Buy\",\"quantity\":\"45000\",\"post_holding\":\"2761308\",\"date\":\"02-Feb-2026\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"TENSHI PHARMACEUTICALS PRIVATE LIMITED\",\"category\":\"Promoters\",\"type\":\"Buy\",\"quantity\":\"205000\",\"post_holding\":\"21004714\",\"date\":\"02-Feb-2026\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Tenshi Pharmaceuticals Private Limited\",\"category\":\"Promoters\",\"type\":\"Buy\",\"quantity\":\"200000\",\"post_holding\":\"20724714\",\"date\":\"28-Jan-2026\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":30.47,\"public_pct\":69.53,\"fii_pct\":19.46,\"dii_pct\":24.21,\"mf_pct\":13.76,\"institutional_pct\":43.67,\"noninst_pct\":25.86,\"mf_scheme_count\":25,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"MOTILAL OSWAL MUTUAL FUND\",\"shares\":8049139,\"pct\":7.02},{\"name\":\"AXIS MUTUAL FUND\",\"shares\":1587678,\"pct\":1.38},{\"name\":\"360 ONE MUTUAL FUND\",\"shares\":1425347,\"pct\":1.24},{\"name\":\"MIRAE ASSET\",\"shares\":1290514,\"pct\":1.13}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742818_21102026031128_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":30.48,\"previous_fii_pct\":19.19,\"previous_dii_pct\":23.38,\"previous_mf_pct\":12.98,\"previous_institutional_pct\":42.57,\"previous_mf_scheme_count\":23,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Onesource Specialty Pharma has risen 18.79% over 5 trading sessions. Today it is 0.97% higher at \u20b91,584.80. See price context, volume and key company.<\/p>\n","protected":false},"author":1,"featured_media":10005,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Onesource Specialty Pharma Share Price Today: Rises 18.79% in 5 Trading Sessions | 30 October 2026","_witty_meta_description":"Onesource Specialty Pharma has risen 18.79% over 5 trading sessions. Today it is 0.97% higher at \u20b91,584.80. See price context, volume and key company.","_witty_primary_phrase":"Onesource Specialty Pharma share price today","_witty_reason_label":"Positive regulatory update and follow-through from strong Q2 earnings within a gaining pharma sector","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[290],"class_list":["post-10006","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-onesource"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=10006"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10006\/revisions"}],"predecessor-version":[{"id":10007,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10006\/revisions\/10007"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/10005"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=10006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=10006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=10006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}